Is ImmunityBio Inc. (IBRX) One of the Best Momentum Stocks to Buy According to Analysts?

ImmunityBio Inc. (NASDAQ:IBRX) is one of the best momentum stocks to buy according to analysts. ImmunityBio Inc. (NASDAQ:IBRX) announced on May 19 that the U.S. Food and Drug Administration accepted for review the supplemental Biologics License Application for ANKTIVA® in combination with Bacillus Calmette-Guerin to treat patients with BCG-unresponsive non-muscle invasive bladder cancer with papillary disease without carcinoma in situ. Management stated that the FDA assigned a PDUFA target action date of January 6, 2027, and that the supplemental BLA seeks to expand the ANKTIVA label to include patients with BCG-unresponsive NMIBC with papillary disease.

ImmunityBio (IBRX) Jumps 18% on Anktiva Access Expansion

In a separate development, ImmunityBio Inc. (NASDAQ:IBRX) received a rating update from BTIG following the release of financial results for fiscal Q1. The firm cut the price target on the stock to $12 from $13, maintaining a Buy rating on the shares. It also reaffirmed the $44.2M in ANKTIVA sales pre-announced last month, which was up 15% q/q and 168% y/y.

ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage immunotherapy company that develops next-generation therapies to treat cancer and infectious diseases. Its immunotherapy platform activates the adaptive and innate immune systems to create long-term immunological memory.

While we acknowledge the risk and potential of IBRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IBRX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1